Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79


A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.

Okal A, Mossalam M, Matissek KJ, Dixon AS, Moos PJ, Lim CS.

Mol Pharm. 2013 Oct 7;10(10):3922-33. doi: 10.1021/mp400379c. Epub 2013 Sep 9.


Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.

Okal A, Cornillie S, Matissek SJ, Matissek KJ, Cheatham TE 3rd, Lim CS.

Mol Pharm. 2014 Jul 7;11(7):2442-52. doi: 10.1021/mp500202p. Epub 2014 May 29.


Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.

Okal A, Matissek KJ, Matissek SJ, Price R, Salama ME, Janát-Amsbury MM, Lim CS.

Gene Ther. 2014 Oct;21(10):903-12. doi: 10.1038/gt.2014.70. Epub 2014 Jul 31.


The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.

Matissek KJ, Mossalam M, Okal A, Lim CS.

Mol Pharm. 2013 Oct 7;10(10):3592-602. doi: 10.1021/mp400380s. Epub 2013 Sep 6.


Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.

Stavridi ES, Chehab NH, Caruso LC, Halazonetis TD.

Protein Sci. 1999 Sep;8(9):1773-9.


An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells.

Hastie E, Cataldi M, Steuerwald N, Grdzelishvili VZ.

Virology. 2015 Sep;483:126-40. doi: 10.1016/j.virol.2015.04.017. Epub 2015 May 15.


Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide.

Senatus PB, Li Y, Mandigo C, Nichols G, Moise G, Mao Y, Brown MD, Anderson RC, Parsa AT, Brandt-Rauf PW, Bruce JN, Fine RL.

Mol Cancer Ther. 2006 Jan;5(1):20-8.


Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.

Wesierska-Gadek J, Schmid G.

Cell Mol Biol Lett. 2001;6(2):117-40.


Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain.

Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP.

Mol Cell Biol. 1998 Jul;18(7):3735-43.


Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells.

David-Pfeuty T, Chakrani F, Ory K, Nouvian-Dooghe Y.

Cell Growth Differ. 1996 Sep;7(9):1211-25.


Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.

Deb D, Scian M, Roth KE, Li W, Keiger J, Chakraborti AS, Deb SP, Deb S.

Oncogene. 2002 Jan 10;21(2):176-89.


Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.

Pratt MA, White D, Kushwaha N, Tibbo E, Niu MY.

Apoptosis. 2007 Apr;12(4):657-69.


The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.

Goldschneider D, Million K, Meiller A, Haddada H, Puisieux A, Bénard J, May E, Douc-Rasy S.

J Cell Sci. 2005 Mar 15;118(Pt 6):1245-53. Epub 2005 Mar 1.


Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.

Montano X.

Oncogene. 2009 Oct 29;28(43):3787-800. doi: 10.1038/onc.2009.143. Epub 2009 Sep 14.


The Meq oncoprotein of Marek's disease virus interacts with p53 and inhibits its transcriptional and apoptotic activities.

Deng X, Li X, Shen Y, Qiu Y, Shi Z, Shao D, Jin Y, Chen H, Ding C, Li L, Chen P, Ma Z.

Virol J. 2010 Nov 26;7:348. doi: 10.1186/1743-422X-7-348.


The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication.

Duan L, Ozaki I, Oakes JW, Taylor JP, Khalili K, Pomerantz RJ.

J Virol. 1994 Jul;68(7):4302-13.

Supplemental Content

Support Center